JP2013100285A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013100285A5 JP2013100285A5 JP2012251584A JP2012251584A JP2013100285A5 JP 2013100285 A5 JP2013100285 A5 JP 2013100285A5 JP 2012251584 A JP2012251584 A JP 2012251584A JP 2012251584 A JP2012251584 A JP 2012251584A JP 2013100285 A5 JP2013100285 A5 JP 2013100285A5
- Authority
- JP
- Japan
- Prior art keywords
- procaspase
- hydrogen
- compound
- allyl
- halogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 40
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 22
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002431 hydrogen Chemical group 0.000 claims 22
- 102000003952 Caspase 3 Human genes 0.000 claims 21
- 108090000397 Caspase 3 Proteins 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 16
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 15
- 150000002367 halogens Chemical group 0.000 claims 15
- 230000000694 effects Effects 0.000 claims 12
- 125000003342 alkenyl group Chemical group 0.000 claims 8
- 125000000262 haloalkenyl group Chemical group 0.000 claims 8
- 125000001188 haloalkyl group Chemical group 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 230000003213 activating effect Effects 0.000 claims 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 7
- 150000002148 esters Chemical class 0.000 claims 7
- 229910052760 oxygen Inorganic materials 0.000 claims 7
- 239000001301 oxygen Substances 0.000 claims 7
- 230000004962 physiological condition Effects 0.000 claims 7
- 229910052717 sulfur Inorganic materials 0.000 claims 7
- 239000011593 sulfur Substances 0.000 claims 7
- YQNRVGJCPCNMKT-LFVJCYFKSA-N 2-[(e)-[[2-(4-benzylpiperazin-1-ium-1-yl)acetyl]hydrazinylidene]methyl]-6-prop-2-enylphenolate Chemical compound [O-]C1=C(CC=C)C=CC=C1\C=N\NC(=O)C[NH+]1CCN(CC=2C=CC=CC=2)CC1 YQNRVGJCPCNMKT-LFVJCYFKSA-N 0.000 claims 6
- 101000838335 Homo sapiens Dual specificity protein phosphatase 2 Proteins 0.000 claims 6
- 101001080401 Homo sapiens Proteasome assembly chaperone 1 Proteins 0.000 claims 6
- 229960005552 PAC-1 Drugs 0.000 claims 6
- 102100027583 Proteasome assembly chaperone 1 Human genes 0.000 claims 6
- 238000012216 screening Methods 0.000 claims 6
- 102000004041 Caspase 7 Human genes 0.000 claims 5
- 108090000567 Caspase 7 Proteins 0.000 claims 5
- -1 Thereby Chemical class 0.000 claims 3
- 230000006907 apoptotic process Effects 0.000 claims 3
- 239000012190 activator Substances 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 230000002194 synthesizing effect Effects 0.000 claims 2
- 102000004046 Caspase-2 Human genes 0.000 claims 1
- 108090000552 Caspase-2 Proteins 0.000 claims 1
- 102000004091 Caspase-8 Human genes 0.000 claims 1
- 108090000538 Caspase-8 Proteins 0.000 claims 1
- 102000004039 Caspase-9 Human genes 0.000 claims 1
- 108090000566 Caspase-9 Proteins 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000003833 cell viability Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- 230000034994 death Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000035945 sensitivity Effects 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68480705P | 2005-05-26 | 2005-05-26 | |
| US60/684,807 | 2005-05-26 | ||
| US74387806P | 2006-03-28 | 2006-03-28 | |
| US60/743,878 | 2006-03-28 | ||
| US11/420,425 | 2006-05-25 | ||
| US11/420,425 US20070049602A1 (en) | 2005-05-26 | 2006-05-25 | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513829A Division JP5513741B2 (ja) | 2005-05-26 | 2006-05-26 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013100285A JP2013100285A (ja) | 2013-05-23 |
| JP2013100285A5 true JP2013100285A5 (enExample) | 2013-08-15 |
| JP5907852B2 JP5907852B2 (ja) | 2016-04-26 |
Family
ID=37452994
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513829A Active JP5513741B2 (ja) | 2005-05-26 | 2006-05-26 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
| JP2012251584A Active JP5907852B2 (ja) | 2005-05-26 | 2012-11-15 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008513829A Active JP5513741B2 (ja) | 2005-05-26 | 2006-05-26 | プロカスパーゼ−３の活性化を含む、癌細胞における選択的アポトーシス誘導 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20070049602A1 (enExample) |
| EP (3) | EP2634581A1 (enExample) |
| JP (2) | JP5513741B2 (enExample) |
| AU (1) | AU2006251978A1 (enExample) |
| CA (1) | CA2610366A1 (enExample) |
| DK (1) | DK1893210T3 (enExample) |
| ES (1) | ES2763156T3 (enExample) |
| IL (1) | IL187603A0 (enExample) |
| MX (1) | MX2007014843A (enExample) |
| WO (1) | WO2006128173A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008134474A2 (en) | 2007-04-27 | 2008-11-06 | The Board Of Trustees Of The University Of Illinois | Compositions and methods including cell death inducers and procaspase activation |
| US20070049602A1 (en) * | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
| BRPI1008651B1 (pt) | 2009-02-09 | 2020-01-21 | Univ Illinois | compostos ativadores de procaspase, medicamento que os compreende e uso dos mesmos |
| WO2010102513A1 (zh) * | 2009-03-11 | 2010-09-16 | 深圳市湘雅生物医药研究院 | 高哌嗪乙酰肼类衍生物及其制备方法和用途 |
| CN101805338B (zh) * | 2010-04-06 | 2014-10-15 | 沈阳药科大学 | 噁二唑基哌嗪衍生物及其用途 |
| US8916705B2 (en) * | 2011-10-14 | 2014-12-23 | The Board of Trustees of The University of Illilnois | Procaspase-activating compounds and compositions |
| CN104487059B (zh) | 2012-03-02 | 2017-06-23 | 伊利诺伊大学评议会 | 由双重化合物激活的强有效的抗癌活性 |
| KR102074530B1 (ko) * | 2012-03-06 | 2020-02-06 | 더 보드 오브 트러스티즈 오브 더 유니버시티 오브 일리노이 | 조합 요법에 의한 프로카스파제 ３ 활성화 |
| US9421202B2 (en) * | 2012-03-06 | 2016-08-23 | The Board Of Trustees Of The University Of Illinois | Procaspase combination therapy for glioblastoma |
| US9249116B2 (en) | 2012-08-03 | 2016-02-02 | The Board Of Trustees Of The University Of Illinois | Enzyme-activating compounds and compositions |
| CN105218399B (zh) | 2014-05-30 | 2018-02-09 | 中国人民解放军军事医学科学院毒物药物研究所 | 一种取代乙酰肼类衍生物、其制备方法及用途 |
| EP3302478B1 (en) | 2015-06-05 | 2021-11-17 | The Board of Trustees of the University of Illinois | Pac-1 combination therapy |
| EP3326631B1 (en) * | 2015-07-23 | 2021-07-14 | Zhimin Wang | Compound pac-1 or salt thereof, and pharmaceutical composition comprising same |
| US10561667B2 (en) | 2015-07-24 | 2020-02-18 | Shenzhen Zhenxing Medical Technology Co., Ltd. | Orbit azine-fumarate, hydrate, crystal form and preparation method therefor |
| CN105085421B (zh) * | 2015-07-24 | 2017-12-26 | 深圳市湘雅生物医药研究院 | 奥比特嗪‑富马酸盐、水合物、晶型及其制备方法 |
| CA3082575A1 (en) | 2017-11-17 | 2019-05-23 | The Board Of Trustees Of The University Of Illinois | Cancer therapy by degrading dual mek signaling |
| US12090153B2 (en) | 2018-10-05 | 2024-09-17 | The Board Of Trustees Of The University Of Illinois | Combination therapy for the treatment of uveal melanoma |
| WO2025129066A1 (en) * | 2023-12-15 | 2025-06-19 | The Regents Of The University Of California | Detection, prevention, and reversal of acquired resistance to immune checkpoint blockade therapy |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU760765B2 (en) * | 1997-05-22 | 2003-05-22 | Burnham Institute, The | Screening assays for agents that alter inhibitor of apoptosis (IAP) protein regulation of caspase activity |
| US6403765B1 (en) | 1998-06-16 | 2002-06-11 | Thomas Jefferson University | Truncated Apaf-1 and methods of use thereof |
| AU5205499A (en) | 1998-07-27 | 2000-02-21 | Pharmacia & Upjohn Company | Method for autoactivation of procaspase 8 |
| US6110691A (en) | 2000-01-06 | 2000-08-29 | Board Of Regents, The University Of Texas System | Activators of caspases |
| US6608026B1 (en) | 2000-08-23 | 2003-08-19 | Board Of Regents, The University Of Texas System | Apoptotic compounds |
| WO2002048329A2 (en) | 2000-11-20 | 2002-06-20 | Idun Pharmaceuticals, Inc. | Membrane derived caspase-3, compositions comprising the same and methods of use therefor |
| US20020115613A1 (en) * | 2001-02-16 | 2002-08-22 | Kumar M. Vijay | Treatment of prostate cancer |
| KR100439425B1 (ko) * | 2001-03-22 | 2004-07-05 | (주)바이오케어 | 잔토리졸을 포함하는 조성물 및 그 용도 |
| WO2003024955A2 (en) | 2001-09-18 | 2003-03-27 | Sunesis Pharmaceuticals, Inc. | Small molecule inhibitors of caspases |
| US20060100131A1 (en) * | 2002-12-10 | 2006-05-11 | Lynn Megeney | Modulation of stem cell differentiation by modulation of caspase-3 activity |
| WO2004066958A2 (en) | 2003-01-30 | 2004-08-12 | The Trustees Of Princeton University | Caspase-9:bir3 domain of xiap complexes and methods of use |
| US20070049602A1 (en) * | 2005-05-26 | 2007-03-01 | The Board Of Trustees Of The University Of Illinois | Selective Apoptotic Induction in Cancer Cells Including Activation of Procaspase-3 |
-
2006
- 2006-05-25 US US11/420,425 patent/US20070049602A1/en not_active Abandoned
- 2006-05-26 AU AU2006251978A patent/AU2006251978A1/en not_active Abandoned
- 2006-05-26 EP EP13166147.2A patent/EP2634581A1/en not_active Withdrawn
- 2006-05-26 WO PCT/US2006/020910 patent/WO2006128173A2/en not_active Ceased
- 2006-05-26 MX MX2007014843A patent/MX2007014843A/es not_active Application Discontinuation
- 2006-05-26 CA CA002610366A patent/CA2610366A1/en not_active Abandoned
- 2006-05-26 DK DK06771588.8T patent/DK1893210T3/da active
- 2006-05-26 ES ES06771588T patent/ES2763156T3/es active Active
- 2006-05-26 EP EP06771588.8A patent/EP1893210B1/en active Active
- 2006-05-26 JP JP2008513829A patent/JP5513741B2/ja active Active
- 2006-05-26 EP EP13166145.6A patent/EP2659884A3/en not_active Withdrawn
-
2007
- 2007-11-25 IL IL187603A patent/IL187603A0/en unknown
-
2012
- 2012-11-15 JP JP2012251584A patent/JP5907852B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013100285A5 (enExample) | ||
| Reuten et al. | Basement membrane stiffness determines metastases formation | |
| Ogrodnik et al. | Obesity-induced cellular senescence drives anxiety and impairs neurogenesis | |
| US11260078B2 (en) | Method of treating senescence with multi-stage longevity therapeutics | |
| Jin et al. | Kidney injury molecule-1 and osteopontin: new markers for prediction of early kidney transplant rejection | |
| An et al. | Penta-fluorophenol: a Smiles rearrangement-inspired cysteine-selective fluorescent probe for imaging of human glioblastoma | |
| Chen et al. | Label-free imaging of heme dynamics in living organisms by transient absorption microscopy | |
| AR107561A2 (es) | Ensayo elisa para la detección de vegf | |
| Hanna et al. | Structural remodeling of coronary resistance arteries: effects of age and exercise training | |
| Ando et al. | Meflin is a marker of pancreatic stellate cells involved in fibrosis and epithelial regeneration in the pancreas | |
| EP1810026A4 (en) | B7-H1 AND METHOD FOR THE DIAGNOSIS, FORECAST AND TREATMENT OF CANCER | |
| JP2011528442A5 (enExample) | ||
| Tosetti et al. | Evaluation of three “beyond Baveno VI” criteria to safely spare endoscopies in compensated advanced chronic liver disease | |
| RU2014105558A (ru) | Диагностика болезни альцгеймера | |
| Carotti et al. | Reelin expression in human liver of patients with chronic hepatitis C infection | |
| Kataoka et al. | Glomerular hyperfiltration and hypertrophy: an evaluation of maximum values in pathological indicators to discriminate “diseased” from “normal” | |
| CN106632188A (zh) | 一类检测甲醛的荧光探针及其制备和应用 | |
| Hasibuzzaman et al. | Association between arsenic exposure and soluble thrombomodulin: a cross sectional study in Bangladesh | |
| Pavelka et al. | Luxembourg Parkinson’s study-comprehensive baseline analysis of Parkinson’s disease and atypical parkinsonism | |
| Kapadia et al. | Tissue mosaicism following stem cell aging: blood as an exemplar | |
| de Latouliere et al. | A bioluminescent mouse model of proliferation to highlight early stages of pancreatic cancer: a suitable tool for preclinical studies | |
| ATE531822T1 (de) | Diagnose von prostatakrebs | |
| Ahmed et al. | Local photocrosslinking of native tissue matrix regulates lung epithelial cell mechanosensing and function | |
| ATE470152T1 (de) | Diagnostikverfahren mittels messungen der antiglykan-antikörper-spiegeln | |
| Hassan et al. | Noninvasive fibrosis scores as prognostic markers for varices needing treatment in advanced compensated liver cirrhosis |